06 Sep, 2023 08:52 AM
SYDNEY, AUSTRALIA – 6 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical stage biotechnology company developing nov...read more
01 Aug, 2023 12:10 PM
SYDNEY, AUSTRALIA – 1 August 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel ...read more
28 Jul, 2023 08:58 AM
SYDNEY, AUSTRALIA – 28 July 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more
28 Jun, 2023 02:37 PM
SYDNEY, AUSTRALIA – 27 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disea...read more
27 Jun, 2023 02:37 PM
SYDNEY, AUSTRALIA – 27 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disea...read more
27 Jun, 2023 08:16 AM
On Wednesday, 31 May 2023, Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) announced a fully underwritten placement to institutional investors (Placement) and 1 for 7.6 pro rata ...read more
20 Jun, 2023 02:43 PM
SYDNEY, AUSTRALIA – 20 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage
biotechnology company developing novel LAG-3 immunotherapiesfor cancer and autoimmune disea...read more